Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 1/20 | 0.34 |
| ▸ | KCNA3 | P22001 | 2/20 | 0.33 |
| ▸ | CBLB | Q13191 | 1/20 | 0.32 |
| ▸ | ILK | Q13418 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.30 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5857988 | 0.83 | NUDT1 (0.36) | NUDT1KCNA3CBLBCYP3A4 | |
| SCHEMBL5858001 | 0.73 | ESR1 (0.34) | — | |
| SCHEMBL11593395 | 0.72 | KCNA3 (0.36) | NUDT1KCNA3 | |
| SCHEMBL23403715 | 0.70 | NUDT1 (0.37) | NUDT1KCNA3CBLBCYP3A4 | |
| SCHEMBL31487673 | 0.70 | NUDT1 (0.34) | NUDT1KCNA3CBLB | |
| SCHEMBL27360214 | 0.69 | NUDT1 (0.43) | NUDT1KCNA3CBLB | |
| SCHEMBL3195952 | 0.69 | GABRP (0.39) | NUDT1KCNA3CBLB | |
| SCHEMBL11107332 | 0.69 | NUDT1 (0.33) | NUDT1KCNA3CBLB | |
| SCHEMBL22308308 | 0.68 | NUDT1 (0.42) | NUDT1KCNA3CBLBCYP3A4 | |
| SCHEMBL17307548 | 0.68 | CBLB (0.32) | NUDT1KCNA3CBLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7091361-B2 | Compounds and synthesis process | EASTMAN KODAK COMPANY (US) | 2006-08-15 | — | — | US | disclosed |
| WO-2005047271-A1 | PROCESS FOR THE SYNTHESIS OF 6-CHLORO-2,5-DICARBONAMIDOPHENOLS AND BENZOXAZOLE DERIVATIVES AS INTERMEDIATES | EASTMAN KODAK COMPANY (US) | 2005-05-26 | — | — | WO | disclosed |
| US-20050101784-A1 | Compounds and synthesis process | EASTMAN KODAK COMPANY | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101784-A1 | Compounds and synthesis process | CYP2B6, DDC, DAO | NUDT1 650/4885KCNA3 3650/4885CBLB 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.